LISATA THERAPEUTICS, INC. — Director's Dealing 2016

Jan 27, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2016-01-25

Reporting Person: MYERS STEVEN S (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-01-25	Common Stock	A	9000	—	Acquired	311931	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-25	Options to Purchase Common Stock	$0.63	A	15000	Acquired	2026-01-25	Common Stock (15000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	84331	Indirect
Common Stock	8012	Indirect
Common Stock	19531	Indirect

Footnotes

F1: Represents 9,000 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. The shares restricted stock will all vest on January 25, 2017.

F2: Includes 9,000 shares of unvested restricted stock.